Stock comparison
IDEXX Laboratories
Sarepta Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
SRPT
Sarepta Therapeutics
Market cap
$1.77B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | SRPT | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 40D | IDXX |
| Benjamin Graham | 80A | 47D | IDXX |
| Philip Fisher | 75B | 51C | IDXX |
| Peter Lynch | 71B | 59C | IDXX |
| Joel Greenblatt | 83C | 7F | IDXX |
| Charlie Munger | 87A | 39D | IDXX |
| Terry Smith | 84A | 33F | IDXX |
Side-by-side metrics
| Metric | IDXX | SRPT |
|---|---|---|
| Market cap | $44.12B | $1.77B |
| P/E (TTM) | 39.0x | 31.3x |
| EV/EBIT | 31.6x | - |
| ROIC (TTM) | 40.66% | -1.53% |
| Gross margin | 62.05% | 62.39% |
| Net margin | 24.63% | 2.98% |
| Revenue CAGR 5y | 7.56% | 33.03% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- ROIC (TTM)40.66%vs -1.53%+104%
- Market cap$44.12Bvs $1.77B+96%
- Net margin24.63%vs 2.98%+88%
SRPT leads on
- EV/EBIT-vs 31.6x+113%
- Revenue CAGR 5y33.03%vs 7.56%+77%
- P/E (TTM)31.3xvs 39.0x+20%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.